AI-generated summary
The authors report a nonrandomized case study of 50 COVID-19-positive patients treated with whole-organ transdermal photobiomodulation using alternating red and near-infrared light. They report reduced symptom duration and severity, with most patients recovering within three weeks. Because the study had no randomized or control group, these observations cannot establish whether the treatment itself caused the improvement.
- Participants
- 50
- Who or what was studied
- 50 COVID-19-positive patients
- Wavelengths
- 650, 850 nm
- Limits stated in the abstract
- The study was nonrandomized, had no control group, and involved a small sample of 50 patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
A nonrandomized 50-person case study of COVID-19-positive patients was conducted employing (for the first time) a regimen of whole-organ deep-tissue transdermal dynamic photobiomodulation (PBM) as a primary (or exclusive) therapeutic modality in the treatment of coronavirus. Therapy sessions comprised algorithmically alternating red (650 nm) and near-infrared (NIR; 850 nm) LEDs with an average irradiance of 11 mW/cm2 dynamically sequenced at multiple pulse frequencies. Delivered via 3D bendable polymeric pads maintaining orthogonal optical incidence to body contours over 1,000 cm2 , a single 84-minute session concurrently delivered 20 kJ to the sinuses and 15 kJ to each lung at skin temperatures below 42°C. Therapeutic outcomes observed include significant reductions in the duration and severity of disease symptoms. Acute conditions including fever, body aches (BA) and respiratory distress comprising paroxysmal coughing; lung congestion, dyspnea and hypoxia; sinus congestion; acute eye inflammation; and extreme malaise were eliminated in 41/50 patients within 4 days of commencing PBM treatments with 50/50 patients fully recovering within 3 weeks with no supplemental oxygen requirements. SpO2 concentrations improved as much as 9 points (average 2.5 points) across the entire study population. The PBM sessions required to completely resolve COVID-19 conditions appears monotonically correlated to the time-to-treatment (TTTx)-the delay between the onset of a patient's symptoms and commencing PBM therapy. In contrast, acute inflammatory symptoms were resolved within 4 days irrespective of TTTx.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nm, 850 nm
- Power density (irradiance)
- 11 mW/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Inflammation, Irradiance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.